Effect of vitamin D analogue therapy in a patient with autosomal dominant hypocalcaemia type 2 (ADH2) due to GNA11 p.Arg60Leu mutation

Catriona Farrell, Fadil Hannan, Jacob George, Emma Robinson, Joanne Mclean, Hannah Boon, Treena Cranston, David Goudie, Rajesh Thakker, Paul Newey

Research output: Contribution to journalArticlepeer-review


Background: Autosomal dominant hypocalcaemia (ADH) is most commonly due to activating mutations in the Calcium Sensing Receptor (ADH Type 1), in which treatment with vitamin D analogues is frequently associated with hypercalciuria. More recently, activating mutations in the alpha-subunit of the G-protein α-11 (Gα11), encoded by GNA11, have been identified in a small number of ADH kindreds (ADH Type 2). The impact of vitamin D analogue treatment in ADH2 patients has not been evaluated.

Case Report: The proband, a 46-year-old female, was incidentally found to be hypocalcaemic. Clinical assessment revealed that she was experiencing intermittent paresthesia and cramping of the digits. Baseline biochemical testing confirmed a reduced serum corrected calcium (1.79 mmol/l; NR 2.1–2.55 mmol/l), raised serum phosphate (2.05; NR 0.8–1.5 mmol/l), low plasma PTH (1.0 pmol/l; NR 1.5–7.6 pmol/l), and low urine calcium:creatinine (U.Ca:Creat) ratio (0.2; NR 0.3–0.7). Her father had been on long-term calcium supplementation raising the possibility of a dominantly inherited hypocalcaemic disorder. Subsequent gene-panel testing revealed a pathogenic GNA11 variant (c.179G>T; p.Arg60Leu) establishing the diagnosis of ADH2. The patient was treated with calcitriol (with ≥1000 mg dietary/oral calcium/day) to relieve hypocalcaemic symptoms and has been monitored for >21 months with serum and urine calcium measurements. The calcitriol dose was progressively increased from 250 ng daily to 1000 ng daily, which improved symptoms, and increased her serum calcium in a dose-dependent manner from 1.79 to 2.09 mmol/l. This was not associated with consistent alterations in serum phosphate or PTH. However, treatment with calcitriol 1000 ng daily increased her U.Ca:Creat ratio to 0.5 and was associated with hypercalciuria (24 hour urine calcium >0.1 mmol/kg per 24 h), despite failing to normalise serum calcium concentration.

Conclusions: Although vitamin D analogue therapy may alleviate symptoms and improve hypocalcaemia in patients with ADH2, caution is required as hypercalciuria may occur, even when serum calcium is below the reference range.


Dive into the research topics of 'Effect of vitamin D analogue therapy in a patient with autosomal dominant hypocalcaemia type 2 (ADH2) due to GNA11 p.Arg60Leu mutation'. Together they form a unique fingerprint.

Cite this